Health Catalyst, Inc. (HCAT)
| Market Cap | 130.95M -41.5% |
| Revenue (ttm) | 292.25M -7.5% |
| Net Income | -264.82M |
| EPS | -3.68 |
| Shares Out | 75.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 165,623 |
| Open | 1.750 |
| Previous Close | 1.740 |
| Day's Range | 1.710 - 1.775 |
| 52-Week Range | 0.955 - 3.615 |
| Beta | 1.54 |
| Analysts | Hold |
| Price Target | 1.77 (+1.72%) |
| Earnings Date | Nov 5, 2026 |
About HCAT
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. It offers ignite data and analytics platform that provides clients a single comprehensive environment to integrate and organize data from their disparate software systems; and applications, a software analytics applications build for ignite platform to analyze clients face across clinical improvement, revenue and cost improvement, ambulatory operat... [Read more]
Financial Performance
In 2025, Health Catalyst's revenue was $311.14 million, an increase of 1.48% compared to the previous year's $306.58 million. Losses were -$177.97 million, 156.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for HCAT stock is "Hold." The 12-month stock price target is $1.77, which is an increase of 1.72% from the latest price.
News
Health Catalyst to Announce Third Quarter 2026 Operating Results and Host Conference Call on Thursday, November 5, 2026
SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health sy...
Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SALT LAKE CITY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improve...
Health Catalyst Strengthens Its Board with the Appointment of Tami Reller
Reller Joins Health Catalyst as it Enters Its Next Phase of Growth SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", NASDAQ: HCAT), a healthcare intelligence com...
Health Catalyst CEO Ben Albert to transition out of role, Simeon Kohl to succeed
Health Catalyst (HCAT) announced that Simeon Kohl has been appointed CEO and president and a member of the company’s board of directors, effective September 14. Simeon Kohl most recently served…
Health Catalyst Appoints Simeon Kohl as Chief Executive Officer and President
SALT LAKE CITY, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improve...
Health Catalyst to Participate in Upcoming Investor Conference
SALT LAKE CITY, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health sy...
Canaccord downgrades Health Catalyst to Hold on transformation risk
Canaccord downgraded Health Catalyst (HCAT) to Hold from Buy with a price target of $1.80, down from $3. The company is working through uncertainty around churn and down-sell risk among…
Health Catalyst downgraded to Hold from Buy at Canaccord
Canaccord analyst Richard Close downgraded Health Catalyst (HCAT) to Hold from Buy with a price target of $1.80, down from $3.
Health Catalyst price target lowered to $2 from $2.50 at Citi
Citi analyst Daniel Grosslight lowered the firm’s price target on Health Catalyst (HCAT) to $2 from $2.50 and keeps a Neutral rating on the shares. The firm updated its ratings…
Health Catalyst completes sale of Vitalware for $147M
Health Catalyst (HCAT) announced it closed the sale of Vitalware, through which the company conducted its Vitalware business, to Med-Metrix, a technology-enabled revenue cycle management company, on J...
Health Catalyst sees FY26 revenue $246M-$249M, consensus $266.93M
Sees FY26 adjusted EBITDA $18M to $18.5M.
Health Catalyst Earnings Call Transcript: Q2 2026
Q2 2026 results exceeded revenue and adjusted EBITDA guidance, driven by strong execution and the Vitalware divestiture, which enabled full debt repayment and a debt-free balance sheet. Updated 2026 guidance reflects the removal of Vitalware, ongoing migration costs, and continued investment in core technology and talent.
Health Catalyst Earnings release: Q2 2026
Health Catalyst released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Health Catalyst Quarterly report: Q2 2026
Health Catalyst has published its Q2 2026 quarterly earnings report on August 6, 2026.
Health Catalyst reports Q2 adjusted EPS 4c, consensus 3c
Reports Q2 revenue $70.49M, consensus $68.94M. The company recently closed the Vitalware divestiture and fully repaid its credit facility debt, which improves its balance sheet and provides flexibilit...
Health Catalyst sees Q3 revenue $55M-$56M, consensus $62.91M
Sees Q3 adjusted EBITDA $0-$500K.
Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company
Company retires all credit facility debt; transaction reflects concentrating its technology on improving health system performance. SALT LAKE CITY, Aug. 6, 2026 /PRNewswire/ -- Health Catalyst, Inc. (...
Health Catalyst Reports Second Quarter 2026 Results
SALT LAKE CITY, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health sy...
Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026
SALT LAKE CITY, July 28, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health sy...
Health Catalyst price target raised to $2.50 from $1.75 at Citi
Citi raised the firm’s price target on Health Catalyst (HCAT) to $2.50 from $1.75 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the…
Health Catalyst price target raised to $3 from $2 at Canaccord
Canaccord raised the firm’s price target on Health Catalyst (HCAT) to $3 from $2 and keeps a Buy rating on the shares. The firm updated its model heading into the…
Health Catalyst Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and a proposal to phase out the classified board structure. Three proposals passed, while the board structure change did not reach the required approval threshold.
Health Catalyst price target raised to $1.75 from $1 at Wells Fargo
Wells Fargo analyst Stan Berenshteyn raised the firm’s price target on Health Catalyst (HCAT) to $1.75 from $1 and keeps an Equal Weight rating on the shares to account for…
Med-Metrix Enters Into Definitive Agreement to Acquire Vitalware to Enhance Coding Accuracy and Net Revenue Yield
PARSIPPANY, N.J., June 4, 2026 /PRNewswire/ -- Med-Metrix, LLC ("Med-Metrix"), backed by Harvest Partners and A&M Capital Partners, today announced it has entered into a definitive agreement to acquir...
Health Catalyst to divest Vitalware to Med-Metrix for $147M in cash
Health Catalyst (HCAT) announced it has signed a definitive agreement to divest Vitalware and the Vitalware business unit, its mid-revenue cycle business, to Med-Metrix for a total consideration of $1...